Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells

Tze-chen Hsieh1,*, Ching-Jen Yang2, Chia-Yi Lin1, Yong-Syu Lee1 and Joseph M.Wu1
1Department of Biochemistry and Molecular Biology, New York Medical College, Room 133, Valhalla, NY 10595, USA and 2Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
*To whom correspondence should be addressed. Tel: +1 9145944062; Fax: +1 9145944058; Email: tze-chen_hsieh@nymc.edu

Introduction
Quinone reductase 2 (NQO2) is a FAD (flavin adenine dinucleotide)-containing metallo-oxidoreductase discovered in 1961 that has been classified as a phase II detoxification enzyme due to its sequences homology with quinone reductase 1 (NQO1) (1,2). Both NQO1 and NQO2 are cytosolic flavoproteins that catalyze metabolism of quinones; NQO1 utilizes nicotinamide adenine dinucleotide and nicotinamide adenine dinucleotide phosphate as electron donors, whereas NQO2 utilizes N-ribosyl dihydronicotinamide as the electron donor for two- or four-electron reduction of quinones to prevent the formation of potentially harmful semiquinones. Since NQO2 utilizes non-naturally occurring co-substrate N-ribosyl dihydronicotinamide and because the exact identity and nature of quinone substrates for NQO2 remain equivocal, it is debatable whether NQO2 actually functions as a detoxification enzyme in vivo. Recent studies demonstrate that quinone reductases (NQOs) act as a novel redox switch of 20S proteasome in yeast (3) and are also involved in the control of 20S proteasome-mediated degradation of p53/p63 based on studies using cultured keratinocytes from rodents (4,5). Furthermore, NQO1 reportedly blocks 20S proteasomal degradation of tumor suppressor p33[FKBP1] in human melanoma cells (6). These observations suggest that NQOs may participate in the control of stability of proteins via the 20S proteasome (4,7). Conceivably, NQO2 may also be involved in the turnover of proteins playing regulatory roles in various cellular processes including proliferation, cell-cycle arrest, apoptosis and DNA repair.

Overexpression of cyclin D1 is among the most commonly observed alterations in human malignant disorders, linked to their development and progression. Genetic mutations or aberrant control of cyclin D1 expression contribute to increased levels of cyclin D1 and accompanying dysregulation of the G1 → S transition in carcinogenesis. Proteasome-dependent degradation of cyclin D1 is triggered by GSK-3β-mediated phosphorylation at threonine 286 (Thr286), which targets cyclin D1 for ubiquitination and proteolytic degradation (8,9). The activities of cyclin-dependent protein kinases (CDKs) 4/6 are regulated by the abundance of D-type cyclins; cyclin D/CDK4/6 complex in turn controls the phosphorylation of Rb and release of E2F transcription factor as key regulatory steps underlying the G1 → S traverse and consequently uncontrolled proliferation. Evidently, therefore, GSK-3β-mediated cyclin D1 phosphorylation and turnover play an important role in controlling Rb-mediated G1 → S phase transition (9,11).

The chemopreventive activities of resveratrol were first reported on skin and breast carcinomas by Yang et al. (12). Subsequently, resveratrol-mediated anti-prostate cancer (CaP) properties were uncovered by us and others (13–19). Despite evidence demonstrating that resveratrol elicits a wide range of biological functions with multi-system benefits including chemoprevention, cardioprotection, neuroprotection, renal protection and suppression of aging, diabetes, oxidative stress and inflammation (20–25), the mechanism of action of resveratrol remains incomplete. Using resveratrol affinity column combined with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), we recently identified NQO2 as a distinct high affinity resveratrol-targeting protein (26), raising the question whether NQO2 might contribute to the resveratrol-elicited growth and gene control in CaP cells. In the present study, CWR22Rv1 CaP cells expressing NQO2 and containing knockdown NQO2 were used to examine the role of NQO2 in the control of proliferation and cell cycle phase transition. In addition, involvement of NQO2 in the regulation of cyclin D1 turnover via GSK-3β-mediated cyclin D1 phosphorylation and degradation was also investigated. We show that NQO2 plays a role in resveratrol-induced anti-CaP activity by targeting GSK-3β/cyclin D1-mediated cell cycle control via a posttranslational regulatory mechanism coupled to activity of the proteasomes.

Materials and methods
Reagents
Resveratrol was purchased from LKT laboratories (St Paul, MN). The primary antibodies for Rb, cyclin D1, cdk4, cdk6, NQO2, NQO1, GSK-3β, actin and secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The antibody against phosphorylated Rb (Ser780) and Rb (Ser807/811) was from Biosource International (Camarillo, CA). The antibody for AKT, p-cyclin D1 (Thr286) and AKT kinase assay kit were from Cell Signaling Technology (Beverly, MA). Fetal bovine serum, RPMI-1640, penicillin and streptomycin were purchased from Cellgro (Herndon, VA). All other chemicals and solvents used were of analytical grade.

Generation and selection of CWR22Rv1 cells containing stably expressed shRNA-mediated NQO2 knockdown
Human CWR22Rv1 cells were obtained from the American Tissue Culture Collection (Manassas, VA) and maintained in RPMI-1640 supplemented with penicillin, streptomycin and 10% heat-inactivated fetal bovine serum as described (27–29). Stably expressed short hairpin RNA (shRNA)-mediated NQO2-knockdown CWR22Rv1 cells were established using the following procedure. Cells were first seeded at a density of 2 × 105 cells/ml in six-well
plates; following an overnight incubation, cells were transfected with control or NQO2-targeted shRNA using Lipofectamine 2000 transfection reagent and protocol provided by the manufacturer (Invitrogen, Carlsbad, CA). Control shRNA in pGFP-V-RS (GFP plasmid (TR30008, marked as shRNA08) and HuSh 29mer NQO2-targeting shRNA in pGFP-V-RS plasmid (G344425, marked as shRNA25) were obtained from Origene Technologies (Rockville, MD) and used in this study. At 48 h post transfection, selection was initiated with 0.25 μg/ml puromycin (Research Products International Corp., Mt Prospect, IL) for four passages, by serially diluting and seeding cells at sequential passages at a progressively reduced density of 30, 5 and 0.3 cells per well in 96-well plates. Single colonies were picked and transferred into six-well plate for propagation and expression. NQO2-encoding plasmids containing either control shRNA08 or NQO2-targeting shRNA25 were stably expressed and cells were analyzed by fluorescent microscopy. A Zeiss microscope equipped with Axiosvert 200 Imaging System (Carl Zeiss MicroImaging, Jena, Germany) was used to capture cell images at ×10 magnification. Confirmation of NQO2 knockdown by shRNA was based on results of immunoblot analysis. Using this approach, stable control and NQO2-knockdown CWR22Rv1 cell lines were established and used for experiments. They were designated as shRNA08 and shRNA25, respectively.

Preparation of whole-cell extracts and western blot analysis
Cells were collected and lysed by incubation on ice for 30 min in cold immuno-precipitation (RIPA) buffer, which contained 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 0.5% Triton X-100, 1% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM dithiothreitol and 10 μM protease inhibitor cocktail from Sigma–Aldrich Corp. (St Louis, MO). The extracts were centrifuged and the clear supernatants were stored in aliquots at −80°C for further analysis. Protein concentrations of cell lysates were determined by coomassie protein assay kit (Pierce, Rockford, IL) using bovine serum albumin as standard. Aliquots of lysates (10 μg of protein) were resolved by 10% SDS-polycrylamide gel electrophoresis followed by western blot analysis. The blots were first incubated with specific primary antibodies followed by secondary antibodies. Specific immunoreactive bands were identified and detected by enhanced chemiluminescence protocol provided by the manufacturer (Invitrogen, Carlsbad, CA). Control shRNA in pGFP-V-RS plasmid was used as control for normalization of messenger RNA expression results. PCR condition for cyclin D1 expression was: denaturation at 94°C, 5 min, followed by 30 cycles of denaturation at 94°C, each 1 min, 1 min annealing at 60°C and 1 min extension at 72°C. PCR condition for GAPDH expression was: denaturation at 95°C, 5 min, followed by 28 cycles of denaturation at 95°C, each 30 s, 30 s annealing at 60°C and 30 s extension at 72°C.

Results
Generation of stable NQO2-knockdown CWR22Rv1 cell lines
Development of a cell model represents a reasonable approach to study the role of NQO2 in resveratrol-mediated bioactivities including chemoprevention against CaP. To this end, we generated CWR22Rv1 cells harboring stable NQO2 knockdown using NQO2-specific shRNA designed on the basis of NQO2-specific shRNA sequences (shRNA25, shRNA26, shRNA27 and shRNA28) shown in Figure 1A, and the efficacy of NQO2 knockdown was confirmed by immunoblot analysis. While shRNA26 and shRNA27 did not result in knockdown of NQO2 (data not shown), in cells transfected with shRNA25, a ~53% decrease in NQO2 expression without changes in NQO1 was observed, as compared with cells similarly transfected with control shRNA08 (Figure 1B). Surprisingly, cells transfected with NQO2-specific shRNA28 were accompanied by ~82% and ~57% loss of levels of both NQO2 and NQO1 relative to cells transfected with control shRNA08 (Figure 1B). The level of actin was unchanged suggesting specificity of the NQO2 knockdown (Figure 1B). Since transfection by shRNA28 resulted in knockdown of NQO1 and NQO2 expression, we aligned the nucleotide sequence of shRNA25 and 28 against NQO1 and NQO2. Figure 1C showed that the shRNA25 nucleotide sequence was perfectly aligned with NQO2, whereas nucleotides of shRNA28 showed complementarity to both NQO1 and NQO2. Given that stable clones generated also contained the pGFP-RS shRNA expression vector, evident by constitutive expression of GFP under control of the pCMV promoter, GFP fluorescence was used to monitor selection and identification of positive clones (Figure 1D). Whether suppression of NQO2 expression by shRNA also affected its enzyme activity was investigated in control (shRNA08) and NQO2 knockdown (shRNA25) cells. As expected, knockdown of NQO2 resulted in ~50% reduction of its enzyme activity (Figure 1E).
Effects of NQO2 knockdown on proliferation and cell cycle distribution

Using the stable control shRNA08 and NQO2-knockdown shRNA25 clones as models, the effects of NQO2 knockdown on CWR22Rv1 cell proliferation were studied. Knockdown of NQO2 by shRNA25 inhibited growth relative to controls transfected with shRNA08. Compared with time 0, suppression of cell proliferation in shRNA25 cells was evident at 24 h (~17% inhibition; Figure 2A), which increased to ~47% at 48 h (Figure 2A). To further test NQO2 knockdown-induced growth suppressive effects, changes of cell cycle phase distribution

Fig. 1. Generation of NQO2 shRNA CWR22Rv1 cell lines. (A) Sequences of human NQO2 shRNA used for silencing NQO2 in CWR22Rv1 cells. (B) Western blot analysis performed to verify the efficiency of NQO2 knockdown and expression of functionally redundant NQO1 in control shRNA08 and NQO2-knockdown shRNA25 and shRNA28 CWR22Rv1 cells. The blots were stripped and reprobed with actin, which served as a loading control. The intensity of the specific immunoreactive bands was quantified by densitometry and expressed as fold differences against actin. (C) Sequence alignment of human NQO2 shRNA25 and shRNA28 sequences against human NQO1 and NQO2 complementary DNA. (D) Fluorescent images of positive control and stable NQO2-knockdown CWR22Rv1 cells. Stable clone contained the pGFP-RS shRNA expression vector, which constitutively expressed tGFP driven by the pCMV promoter. tGFP-expressing cells (light areas) carried either transfected vector plasmid or shRNA. Expression of GFP fluorescence was used to monitor success and efficacy of NQO2 knockdown and selection of positive clone. (E) NQO2 enzymatic activity in control shRNA08 and NQO2-knockdown shRNA25 cells, as assayed using methods detailed in Materials and methods.

Fig. 2. Effects of NQO2 knockdown on control of cell proliferation and cell cycle phase distribution. (A) Cell growth was monitored in control shRNA08 and NQO2-knockdown shRNA25 cells for up to 72 h; the cell numbers were determined at 24, 48 and 72 h by MTS assay as described in Materials and methods. The proliferation of cells carrying shRNA08 or shRNA25 was measured, normalized and expressed as the ratio against time 0 (set as 1). (B) Cell cycle analysis was performed in control shRNA08 and NQO2-knockdown shRNA25 cells at 72 h and changes in cell cycle distribution were analyzed by flow cytometry, and the percentage of cells in G1, S and G2/M phases were calculated. (C) Western blot analysis of Rb, pRb (Ser780) and pRb (Ser 807/811) expression in control shRNA08 and NQO2-knockdown shRNA25 cells maintained in culture for 24, 48 and 72 h. (D) The total expression of phosphorylated cyclin D1 (Thr286), cyclins D1, cdk4 and cdk6 in shRNA08 and shRNA25 cells at 24, 48 and 72 h as determined by western blot analysis. The intensity of the specific immunoreactive bands was quantified by densitometry and expressed as a fold difference against actin (loading control).
were determined by flow cytometry. The percentage of cells in G0, S and G2 + M phases was quantified and presented in Figure 2B. NQO2 knockdown caused a decrease in S phase cell population at 24 h (32.7% in control versus 22.7% in NQO2 knockdown cells), accompanied by a concomitant accumulation in the G1 phase cell population (43.3% in control versus 52.3% in NQO2 knockdown cells), suggesting that NQO2 knockdown resulted in an altered G1 → S transition. Because phosphorylation of Rb plays a pivotal role in the control of cell progression through the G1 → S checkpoint, we tested whether NQO2 contributed to control of Rb status by measuring changes in pRb/Rb in NQO2 expressing (shRNA08) and knockdown (shRNA25) cells. Western blot analysis showed a significant reduction in hyperphosphorylated Rb at Ser-780 and Ser-807/811, respectively, in NQO2 knockdown shRNA25 cells compared with control shRNA08 cells at 72 h (Figure 2C). Since phosphorylation of Rb is under the control of cdk/cyclin complex, the expression of cyclins D1 and cdk4/6 were analyzed. Results in Figure 2D showed that knockdown of NQO2 caused less pronounced effects on cyclin D1/cdk4 or cyclin D1/cdk6 complexes; whether and how NQO2 status might affect the phosphorylation of cyclin D1 remains unknown. Since cyclin D1 degradation/stability is controlled by phosphorylation at Thr286 in concert with changes in cdk4/6 activity, we analyzed changes in cyclin D1-Thr286 in control shRNA08 and NQO2-knockdown shRNA25 cells. Western blot analysis demonstrated that the expression of p-cyclin D1 (Thr286) was markedly downregulated in NQO2-knockdown shRNA25 cells; in stark contrast to NQO2-expressing shRNA08 cells where no change on cyclin D1 phosphorylation at Thr286 occurred (Figure 2D). These results suggest that knockdown of NQO2 abrogates Rb activation and cyclin D1 degradation via a reduction in phosphorylation activity/capacity; albeit, because both changes in both molecular events did not occur until cells were maintained in culture for 48 and 72 h, they are unlikely to directly contribute to growth suppression or cell cycle arrest observed in NQO2-knockdown shRNA25 cells at 24 h. The observed changes, however, proffer the possibility that NQO2 plays a role in phosphorylation-dependent protein modification reactions and processes.

**Effect of NQO2 knockdown on turnover of cyclin D1**

That NQO2 might contribute to control of cyclin D1 stability was further tested using control shRNA08 and NQO2-knockdown shRNA25 cells treated with cycloheximide. Western blot analysis revealed that cyclin D1 was more stable in NQO2 knockdown cells relative to control cells. As shown in Figure 3A, the half-life of cyclin D1 protein increased from ~0.5 h in control cells to >4 h in NQO2 knockdown cells. This substantial prolongation of half-life of cyclin D1 in cells harboring partial silencing of NQO2 expression prompted us to test whether NQO2 status might affect proteasome activity. Using the chymotrypsin-like proteasome activity assay, we found a 37% decrease in proteasome activity in NQO2-knockdown shRNA25 cells compared with control shRNA08 cells (Figure 3B).

Proteasome activity in both normal shRNA08 and NQO2-knockdown shRNA25 cells was effectively inhibited by proteasome inhibitor MG132 (Figure 3B). Accordingly, the possible involvement of proteasomes in mediating cyclin D1 protein stabilization in control shRNA08 and NQO2-knockdown shRNA25 cells was further tested by exposing cultured cells to MG132 and following cyclin D1 loss by immunoblot analysis. Treatment by MG132 effectively blocked degradation of both p-cyclin D1 (Thr286) and cyclin D1 in control shRNA08 and NQO2-knockdown shRNA25 cells (Figure 3C). Furthermore, relatively less p-cyclin D1 (Thr286) was present in NQO2-knockdown shRNA25 cells compared with control shRNA08 cells (Figure 3C), thereby providing additional evidence that stability of cyclin D1 in NQO2 expressing cells

---

**Fig. 3.** Analysis of stability of cyclin D1 protein in relation to NQO2 knockdown. (A) Effect of cycloheximide on turnover/degradation of cyclin D1 in shRNA08 or shRNA25. Cells were treated with 30 μg/ml cycloheximide to inhibit new protein synthesis for the times indicated and changes in cyclin D1 were analyzed by western blot analysis, with actin expression used as loading control. Cyclin D1 expression was quantified by densitometric analysis and the expression was presented as percentage (%) remaining relative to time 0. (B) Effect of knockdown NQO2 on proteasome activity. Both shRNA08 and shRNA25 cells were treated with or without the addition of proteasome inhibitor MG132 (5 μM) for 4 h. Changes in proteasome activity were measured using chymotrypsin-like proteasome activity assay kit obtained from Promega. (C) Effect of proteasome inhibitor MG132 on degradation of phosphorylated cyclin D1 (Thr286) and cyclin D1 in shRNA08 versus shRNA25. Cells were treated with 5 μM MG132 for 0, 2, 4 and 8 h and changes in protein expression was analyzed by western blot analysis, with actin used as loading control. (D) Effect of proteasome inhibitor MG132 on degradation of Gsk-3β and AKT in shRNA08 versus shRNA25. Cells were treated with 5 μM MG132 for 0, 2, 4 and 8 h and changes in Gsk-3β and AKT expression were analyzed by western blot analysis, using actin as loading control. (E) AKT kinase activity assay was performed and changes of phosphor-GSK-3β (Ser21/9) expression in shRNA08 and shRNA25 cells at 72 h were analyzed by western blot analysis. (F) Reverse transcription–PCR was performed to assess cyclin D1 messenger RNA changes in shRNA08 and shRNA25 cells at 72 h. The expression of GAPDH was used as internal control.
is attributed to posttranslational degradative mechanisms. Conceivably, knockdown of NQO2 impinges on control of cyclin D1 protein stabilization by attenuating cyclin D1 degradation in part and in concert with the abrogation of cyclin D1 phosphorylation at Thr286 (Figure 2E).

Studies have shown that GSK-3β plays a role in phosphorylation of cyclin D1 and control of its stability; moreover, the activity of GSK-3β can be effectively inhibited by upstream kinase (9). Therefore, we next investigated whether the differential expression of cyclin D1 phosphorylation in normal and NQO2 knockdown cells may be due to the changes in proteasome activity. Specifically, the possibility that proteasomes are involved in modulating AKT and GSK-3β protein stabilization and contributing to the effects on cyclin D1 was tested in control shRNA08 and NQO2-knockdown shRNA25 cells exposed to MG132. We found that the status of NQO2 had little effect on GSK-3β and AKT protein stability (Figure 3D). To additionally investigate whether NQO2 is involved in AKT-mediated GSK-3β control, we measured AKT activity in control shRNA08 and NQO2-knockdown shRNA25 cells using an in vitro AKT kinase assay kit (see Materials and methods). Compared with control cells, NQO2 knockdown caused an estimated 1.5-fold increase in phosphorylation of GSK-3α/β at Ser21/9 (Figure 3E), indicating that NQO2 knockdown may be accompanied by an increase in AKT activity concomitant with deactivation of GSK-3 that consequently contributes to the stabilization of cyclin D1 in NQO2-knockdown shRNA25 cells. Notably, these results are consistent with and lend support to the observed inhibition of cyclin D1 phosphorylation in NQO2-knockdown shRNA25 cells (Figure 2E).

Next, we tested whether NQO2 also affected cyclin D1 expression at the transcriptional level by using reverse transcription–PCR to assess changes in cyclin D1 messenger RNA levels. No difference in cyclin D1 messenger RNA expression was observed between control and NQO2 knockdown cells (Figure 3F).

**Role of NQO2 in CWR22Rv1 growth control in response to resveratrol**

To assess the involvement of NQO2 in resveratrol-induced growth suppression, control shRNA08 and NQO2-knockdown shRNA25 cells were exposed to increasing dose of resveratrol. Concentration-dependent inhibition of proliferation by resveratrol occurred in control shRNA08 cells but not in NQO2-knockdown shRNA25 cells (Figure 4A), supporting the premise that NQO2 plays a role in resveratrol-induced growth inhibition.

To further investigate whether NQO2 actively controls resveratrol-induced cell cycle change, flow cytometric analysis was performed. A more pronounced G1 accumulation accompanied by G2/M blockade was found in control cells, as opposed to depletion of S phase in NQO2 knockdown cells, at 72 h exposure to 50 µM resveratrol (Figure 4B). Modulation of sensitivity to resveratrol-induced cell cycle changes by NQO2 knockdown was also evident in analysis of expression of cell cycle regulatory proteins cyclin D1/cdk4 in resveratrol-treated control and NQO2 knockdown cells. Results in Figure 4C show that treatment by resveratrol caused a comparably less pronounced reduction in cyclin D1 and cdk4 expression in NQO2-knockdown shRNA25 cells, relative to NQO2-expressing shRNA08 cells.

**Role of NQO2 on cyclin D1 control in resveratrol-treated cells**

To obtain additional information on whether NQO2 contributes to resveratrol-induced growth control via modulation of cyclin D1 turnover, western blot analyses were performed demonstrating that cyclin D1 protein was more stable in NQO2 knockdown cells compared with control cells. For example, exposure to 10 µM resveratrol sufficed to downregulate cyclin D1 protein expression in control shRNA08, whereas 50 µM resveratrol was required to cause a comparable decrease in cyclin D1 levels in NQO2-knockdown shRNA25 cells (Figure 5A). These results indicate that NQO2 at least in part contributes to resveratrol-induced downregulation of cyclin D1 expression in concordance with the inhibition of cell growth; it may be surmised that at low doses of resveratrol (2.5–10 µM), NQO2 plays an integral role in mediating cyclin D1 expression/stability by resveratrol, whereas at >25 µM resveratrol, control of cyclin D1 occurs independent of the presence of NQO2.

The possibility that proteasomes are involved in resveratrol-mediated cyclin D1 protein degradation was further tested by culturing both cell lines differing in NQO2 status with addition of resveratrol alone or in combination with proteasome inhibitor MG132. Changes of immunoreactive cyclin D1 levels definitively showed that MG132 of resveratrol-induced degradation of cyclin D1 in NQO2-knockdown shRNA25 cells (Figure 5B). In shRNA08, however, MG132 only blocked cyclin D1 degradation at 10 µM but not at 25 µM resveratrol-treated cells (Figure 5B). These results fortify the notion that NQO2 participates in proteasome-mediated degradation of cyclin D1 at low dose of resveratrol (<10 µM); in contrast, at ≥25 µM resveratrol, control of cyclin D1 occurs independent of the presence of NQO2.
NQO2 is supported by recent demonstration that NQOs (NQO1 and NQO2) have distinct roles in the biological function of NQO2. Indeed, yet to be discovered the role of NQO2 extends beyond its traditional biochemical assignment as a phase II enzyme. Unlike the more comprehensively studied phase II enzyme NQO1, which utilizes nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate to carry out the detoxification of harmful oxygen metabolites, NQO2 has always been considered enigmatic as it exclusively uses the unusual, non-naturally occurring co-substrate ribosyl dihydronicotinamide to reduce harmful semiquinones—in part the basis for the ongoing debate as to the ‘real’ physiological and biological function of NQO2.

Resveratrol exerts significant chemopreventive and therapeutic effects in various cancers; however, the mechanisms contributing to its anti-tumorigenic activities are only partially understood. Previously, we have identified NQO2 as a novel resveratrol-targeting protein; details by which NQO2 contributes to resveratrol-mediated anti-CaP activity were investigated in this study. Knockdown of NQO2 in CWR22Rv1 cells resulted in growth suppression, G1 → S arrest as well as downregulation of Rb and cyclin D1 phosphorylation (Figure 2) suggesting that NQO2 plays a role in Rh/cyclin D1-mediated growth arrest and cell cycle control. Overexpression of cyclin D1 is commonly observed in various human cancers and whether NQO2 controls cyclin D1 stability and turnover has not been previously reported. Using knockdown NQO2 cells, we found that cyclin D1 turnover is significantly attenuated in NQO2-knockdown shRNA25 cells. Moreover, NQO2-mediated cyclin D1 degradation can be effectively blocked by proteasome inhibitor MG-132 in NQO2 expression shRNA08 cells (Figure 3B), providing support that NQO2 has an integral role in proteasome-mediated cyclin D1 degradation, and also is an important mediator of resveratrol-mediated growth control via cyclin D1. In previous studies, resveratrol has been reported to effectively downregulate cyclin D1 in various cancer types (34–36). Herein, we demonstrate for the first time that NQO2 participates in resveratrol-induced changes of cyclin D1 level via control of its stability and turnover; knockdown of NQO2 attenuates downregulation of cyclin D1 and similarly abrogates resveratrol-induced growth suppression (Figures 4 and 5).

It is noteworthy that the newly revealed role of NQO2 differs significantly from its traditional biochemical assignment as a phase II detoxification enzyme for protection of cells against free radicals and toxic oxygen metabolites. This may not be all surprising since unlike the more comprehensively studied phase II enzyme NQO1, which utilizes nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate to carry out the detoxification reaction, NQO2 has always been considered enigmatic as it exclusively uses the unusual, non-naturally occurring co-substrate N-ribosyl dihydronicotinamide to reduce harmful semiquinones—in part the basis for the ongoing debate as to the ‘real’ physiological and biological function of NQO2. Indeed, yet to be discovered the role of NQO2 is supported by recent demonstration that NQOs (NQO1 and NQO2) impart stability and protection of tumor suppressor p53 against degradation catalyzed by 20S proteasomes (4). In the current study, we showed that knockdown of NQO2 is accompanied by hyperphosphorylation and deactivation of GSK-3β/ΔSer21/ΔThr, which in turn impinges on cyclin D1 phosphorylation and blocks its degradation by proteasomes. Whether NQO2 facilitates GSK-3β-mediated cyclin D1 proteolysis by direct binding with 20S proteasomes to effect inhibition of proteasomal-mediated protein degradation, by targeted posttranslational modification of cyclin D1, or alternatively by interacting with AKT to suppress its phosphorylation-dependent activation to in turn interfere with phosphorylation of GSK-3β remains to be elucidated. A hypothetic model is shown in Figure 6, depicting these possibilities.

The control of cyclin D1 by NQO2 observed in the present studies may be germane to the previously reported role of NQO2 in protection of degradation of tumor suppressor p53 by 20S proteasomes (4). As noted by Gong et al. (4), both NQO2 and NQO1 confer stability on p53 by preventing 20S proteasomal activity in human hepatoma Hep-G2 cells and keratinocytes obtained from tumors in wild-type, NQO2 null and NQO1-null mice (4). Thus, it is of interest to further analyze control of p53 stability in normal shRNA08 and NQO2-knockdown shRNA25 cells as underscored by the following considerations. First, shRNA28 cells (Figure 1B), uniquely showing both NQO1 and NQO2 knockdowns, might be expected to have least abundantly expressed p53 compared with shRNA08 and shRNA25; this possibility is supported by results of our preliminary analysis (results not shown). Second, compared with wild-type p53, mutant p53 has been shown to display increased binding to NQO1 resulting in its resistance to ubiquitin-independent degradation (37); this observation is of particular relevance to CWR22Rv1 cells, known to contain mutated p53 (38). Finally, as previously suggested, protection of p53 from 20S proteasome-mediated degradation may require its separate but simultaneous interaction with NQO1 and NQO2 (4), suggesting that the cellular level of NQO1 relative to NQO2 may be critically important in modulating the stability of p53 and determining its expressed levels. Accordingly, as applied to CWR22Rv1 cells, p53 may display both increased and decreased expression as reflection of its dynamic and temporal stability and turnover changes, perhaps resulting from redundancy in and/or preferred interaction with NQO1, relative to NQO2. These possibilities and details of the control of p53 stability in normal shRNA08 and NQO2-knockdown shRNA25...
cells are currently under investigation in our laboratory. Since tumor suppressor gene p53 plays an important function in protection of genomic stability, modulation of ubiquitin-independent p53 degradation by NQO2, alone and in partnership with NQO1, offers the intriguing hypothesis that NQOs play a critical yet to be defined role in control of chromosomal integrity and development of genetic variations in normal and diseased cells.

Our results support the interpretation that deletion of NQO2 prevents cyclin D1 phosphorylation and degradation, secondary to inhibition of GSK-3β activity via activation of AKT. The molecular details on how deletion of NQO2 results in AKT activation remain to be investigated and elucidated, especially since it was reported that deletion of several cell survival kinases including AKT by exposure to tumor necrosis factor was effectively abrogated in NQO2-knockdown keratinocytes (39). In unpublished results, we found that NQO2 and AKT coeluted from resveratrol affinity column, suggesting NQO2 may interact with AKT thereby affecting AKT signaling. Moreover, since AKT is considered critical for cancer cell survival, its ability to interact with NQO2 raises the possibility that NQO2 plays a novel role as a cancer risk modulator, with an integral participation in cancer prevention by resveratrol.

When traditional role of NQO2 as a detoxification enzyme is considered in combination with current findings showing that cyclin D1 degradation is regulated by NQO2, it may be surmised that NQO2 contributes to the cancer prevention by direct and indirect mechanisms: (i) NQO2 as a phase II enzyme affords protection against carcinogenicity, mutagenicity and other toxicities caused by carcinogenic xenobiotics; (ii) NQO2 mediates resveratrol-elicted control of cyclin D1 degradation via regulation of stability of cyclin D1; (iii) NQO2 as a distinct resveratrol-targeting protein for resveratrol may also serve as a on/off molecular switch for resveratrol to turn function in its capacity as a phytochemical enzyme activator or inhibitor. Studies to test the added roles of NQO2, in chemoprevention and anti-CaP activities of resveratrol, are underway in our laboratory.

**Funding**

This research was supported in part by the Intramural Sponsored Research Program of New York Medical College to T.-C.H. (49-410-1 and 49-406-1).

**Conflict of Interest Statement:** None declared.

**References**


Received September 1, 2011; revised December 27, 2011; accepted January 15, 2012